Return to homepagePandemic Pact

Rapid Prototyping and Deployment of a Therapeutic Pan-Coronavirus Fusogenix DNA Vaccine Engineered to Eliminate ADE. Dr. John Lewis University of Alberta RNS Funding Contribution: $50,000 Key Words: DNA, Vaccine, COVID-19, Fusogenix

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2021

  • Funder

    Research Nova Scotia

  • Principal Investigator

    Dr. John Lewis

  • Research Location

    N/A

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

DNA, Vaccine, COVID-19, Fusogenix